Doping in sports and methods for its detection

Japanese Journal of Clinical Chemistry

Volumn 36, Issue 3, 2007, Pages 228-235

  Ueki, Makoto ^a  

^a LSI MEDIENCE CORPORATION   (Japan)

Author keywords

Anabolic steroid; Blood transfusion; Designer steroid; Gene doping; HBOCs; ISO17025

Indexed keywords

ANABOLIC AGENT; CENTRAL STIMULANT AGENT;

CHEMICAL STRUCTURE; DOPING; DRUG MISUSE; DRUG SAFETY; DRUG TRAFFIC; GENE THERAPY; INTERNET; PHARMACY; PURCHASING; REVIEW; RISK ASSESSMENT;

EID: 34548030717     PISSN: 03705633     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. WADA: Prohibited List 2007 English version (WADA Official Web Site) http://www.wada-ama.org/rtecontent/document/2007_List_En.pdf
2. http://www.anti-doping.or.jp/code/pdf/2007_ProhibitedList_Jp.pdf
3. Japanese source
4. Japanese source
5. WADA: International Standard for Laboratories version 4, (WADA Official Web Site) http://www.wada-ama.org/en/dynamic.ch2?pageCategory.id=372
6. Japanese source
7. Japanese source
8. Japanese source
9. Japanese source
10. Sekera MH, Ahrens BD, Chang Y, Starcevic B, Georgakopoulos C, Catlin DH: Another designer steroid: discovery, synthesis, and detection of 'madol' in urine, Rapid Commun Mass Spectrom, 19: 781-784, 2005.
11. Japanese source
12. Tripathy SK, Svensson EC, Black HB, Goldwasser E, Margalith M, Hobart PM, Leiden JM: Long-term expression of erythropoietin in systemic circulation of mice after intramuscular injection of a plasmid DNA vector, Proc Nat Acad Sci, 93: 10876-10880, 1996.
13. Lee S, Barton ER, Sweeney HL, Farrar RP: Viral expression of insurin-like growth factor-1 enhances muscle hypertrophy in resistance-trained rats. J App Physiol, 96: 1097-1104, 2004.
14. Lee SJ, McPherron AC: Regulation of myostatin activity and muscle growth, PNAS, 98: 9306-9311, 2001.
15. Barish GD, Narkar VA, Evans RM: PPAR δ : a dragger in the heart of the metabolic syndrome, J Clin Invest, 116: 590-597, 2006.